BOTOX (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Hypertrophy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AbbVie; Allergan
- 13 Dec 2022 Status changed from active, no longer recruiting to completed.
- 24 Jun 2021 Planned End Date changed from 5 Jan 2023 to 17 Nov 2022.
- 24 Jun 2021 Planned primary completion date changed from 5 Jan 2023 to 17 Nov 2022.